Aecom has been appointed project manager on construction of Phase 1a of Bio Istanbul, a $2.2billion (around £1.4bn) development in Turkey.
It will project manage construction of three distinct campuses: the Istanbul Children’s Hospital, a commercial office park focused on research and development, and 150 residential units that will form part of Turkey’s first large-scale community to meet internationally certified sustainability standards LEED and BREEAM.
Aecom will project manage the construction of the campuses through completion and support the client team in the development of the wider site infrastructure planning and delivery.
The appointment comes a year after Davis Langdon, an Aecom company, was appointed cost and programme manager on the project.
“Bio Istanbul has the potential to dramatically improve the level of medical care for the people of Turkey while also positioning Turkey to become the leading centre for pharmaceutical and advanced biomedical research for southeastern Europe and the Middle East,” said Aecom’s managing director for CIS and Turkey David Whitehouse.
“Having worked with Bio City Development Company from the outset of this important project, it is exciting for everyone at AECOM that our role in seeing it successfully delivered has been expanded,” he added.
Chairman and chief executive of Bio Istanbul Tobias Levey said: “We are relying on Aecom to ensure that our ambition for quality in construction is delivered on time and on budget.”
When completed, Bio Istanbul will accommodate 15,000 residents and a further 20,000 working commuters. The facilities’ occupiers will include world-leading pharmaceutical, medical technology and biomedical informatics companies.
Bio Istanbul is a joint venture between the Bio City Development Company, the leading emerging markets’ healthcare infrastructure company; EPP, an affiliate of the Housing Development Administration of Turkey; and the Turkish Ministry of Urbanisation and Environment.